Spots Global Cancer Trial Database for immune checkpoint inhibitors
Every month we try and update this database with for immune checkpoint inhibitors cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Phase II Trial of Consolidative Thoracic Radiotherapy for ES-SCLC After Standard Care of Chemo-immunotherapy | NCT05552846 | Small-cell Lung... | thoracic radiot... | 18 Years - 80 Years | Ruijin Hospital | |
| Improving Patient and Caregiver Understanding of Risks and Benefits of Immunotherapy for Advanced Cancer | NCT04670445 | Stage IV Melano... Advanced Lung C... Stage IV Non-Sm... Unresectable No... Unresectable St... Small Cell Lung... Stage IV Merkel... Stage IV Cutane... Stage IV Basal ... Stage IV Breast... Stage IV Colore... Stage IV Gastri... Stage IV Esopha... Stage IV Hepato... Stage IV Renal ... Stage IV Bladde... Stage IV Head a... Stage IV Cervic... Stage IV Endome... Stage IV Mesoth... Immunotherapy Immune Checkpoi... | Educational Vid... Usual Care | 18 Years - | Massachusetts General Hospital | |
| Dynamics of MSI and Genomic Profile of Colorectal Cancer In the Course of Immune Checkpoint Inhibitor Therapy | NCT06414304 | Colorectal Canc... Colorectal Canc... MSI-H Colorecta... dMMR Colorectal... Cancer Colon Adenocarc... | 18 Years - | OncoAtlas LLC | ||
| Observational Lung Trial to Collect Tissue to Train and Validate a Live Tumor Diagnostic Platform | NCT05478538 | Non Small Cell ... Metastatic Non ... NSCLC Metastatic NSCL... | Core Needle or ... | 18 Years - | Elephas | |
| Exploratory Study on the Therapeutic Effect Prediction Model of Advanced BTC Immunotherapy | NCT06074029 | Biliary Tract C... Immune Checkpoi... Predictive Canc... | Immune Checkpoi... | 18 Years - 80 Years | Peking Union Medical College Hospital | |
| Study of Circulating Tumor DNA (ctDNA) Kinetics in Immuno-oncology (IO-KIN) | NCT04606940 | Head and Neck C... Advanced Cancer Metastatic Canc... HNSCC Squamous Cell C... | 18 Years - | University Health Network, Toronto | ||
| Fertility and Pregnancy After Avelumab Treatment | NCT06242522 | Gestational Tro... Immune Checkpoi... | Telephone inter... | 18 Years - | Hospices Civils de Lyon | |
| Neoadjuvant Aliya™ PEF Soft Tissue Ablation With Systemic Therapy in Early-Stage Resectable NSCLC | NCT05583188 | NSCLC | Aliya Pulsed El... Nivolumab plus ... Standard of car... Surgical Resect... | 18 Years - | Galvanize Therapeutics, Inc. | |
| Adverse Myocardial and Vascular Side Effects of Immune Checkpoint Inhibitors | NCT04586894 | Cancer Immune Defect Cardiovascular ... | Cardiac MRI Smart cloth Biobanking | 18 Years - | Assistance Publique - Hôpitaux de Paris | |
| The ImmunoXXL Study | NCT05879328 | Hepatocellular ... | Liver Transplan... | 18 Years - 75 Years | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | |
| Tislelizumab Combined APF Chemotherapy in the Treatment of Locally Advanced Head and Neck Tumors | NCT05758389 | Head and Neck T... | Tislelizumab, P... | 18 Years - 75 Years | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | |
| Propranolol Hydrochloride and Pembrolizumab in Treating Patients With Stage IIIC-IV Melanoma That Cannot Be Removed by Surgery | NCT03384836 | Stage IIIC Cuta... Stage IV Cutane... | Laboratory Biom... Pembrolizumab Propranolol Hyd... | 18 Years - | Roswell Park Cancer Institute | |
| Cognitive Function in Patients Treated for Metastatic Melanoma With Immune Checkpoint Inhibitors | NCT04565769 | Melanoma Cognitive Impai... Fatigue Sleep Depression, Anx... Quality of Life Inflammation Sickness Behavi... Cancer-related ... | 18 Years - | Aarhus University Hospital | ||
| Atezolizumab in Large Cell Neuroendocrine Carcinoma | NCT06049966 | Large Cell Neur... | Atezolizumab Carboplatin Etoposide | 18 Years - 90 Years | Oncology Center of Biochemical Education And Research | |
| Safety and Preliminary Efficacy of SBRT in Patients With Metastatic RCC Treated With Targeted or IO Therapy | NCT02864615 | Metastatic Rena... | SBRT | 18 Years - 75 Years | Kidney Cancer Research Bureau | |
| Analyzing Clinical Outcomes and Genomic Data of American Indian Patient Population | NCT05863052 | Immune Checkpoi... Metastatic Soli... Nonsmall Cell L... Melanoma Renal Cell Carc... Gastrointestina... Squamous Cell C... | Immunotherapy | 18 Years - 99 Years | University of Oklahoma | |
| Blocking TNF to Potentiate the ICI-dependent Immune Awakening in Melanoma | NCT05867004 | Melanoma Immune Defect Tumor Skin | 18 Years - | Institut Claudius Regaud | ||
| SBRT for Oligoprogressive NSCLC After First Line Treatment With Immune Checkpoint Inhibitors | NCT05387044 | NSCLC Stage IV | SBRT | 18 Years - | Zhejiang Cancer Hospital | |
| Naltrexone and Propranolol Combined With Immunotherapy | NCT05968690 | Advanced Melano... | Propranolol Naltrexone | 18 Years - | Rutgers, The State University of New Jersey | |
| Plasma Biomarker in Predicting Response and Toxicity in HCC Patients Treated With Checkpoint Inhibitors With or Without SBRT | NCT06408753 | Hepatocellular ... Stereotactic Bo... | sterotatic body... | 18 Years - | The University of Hong Kong | |
| Propranolol Hydrochloride and Pembrolizumab in Treating Patients With Stage IIIC-IV Melanoma That Cannot Be Removed by Surgery | NCT03384836 | Stage IIIC Cuta... Stage IV Cutane... | Laboratory Biom... Pembrolizumab Propranolol Hyd... | 18 Years - | Roswell Park Cancer Institute | |
| Immunotherapy for Recurrent Cervical Cancer Refractory to Platinum-based Chemotherapy: Multi-Center Trial | NCT05290935 | Recurrent Cervi... Persistent Adva... Chemotherapy Immune Checkpoi... Anti-PD-1 Antib... Albumin-bound P... | Anti-PD-1 antib... Albumin-bound p... | 18 Years - 75 Years | Peking Union Medical College Hospital | |
| Dynamics of MSI and Genomic Profile of Colorectal Cancer In the Course of Immune Checkpoint Inhibitor Therapy | NCT06414304 | Colorectal Canc... Colorectal Canc... MSI-H Colorecta... dMMR Colorectal... Cancer Colon Adenocarc... | 18 Years - | OncoAtlas LLC | ||
| Autoantibodies in Treatment With Immune Checkpoint Inhibitors (AUTENTIC) | NCT03868046 | Cancer Metastatic Canc... Solid Organ Can... | Treatment with ... Blood tests. | 16 Years - 99 Years | Hospital Universitario Araba | |
| Biomarkers of Immune-Related Toxicity | NCT03409016 | Cancer Metastatic Canc... | Blood Testing | 18 Years - 100 Years | University of Colorado, Denver | |
| Observational Lung Trial to Collect Tissue to Train and Validate a Live Tumor Diagnostic Platform | NCT05478538 | Non Small Cell ... Metastatic Non ... NSCLC Metastatic NSCL... | Core Needle or ... | 18 Years - | Elephas | |
| A Phase Ib/IIa Study of CR6086 in Combination With Balstilimab in pMMR-MSS Metastatic Colorectal Cancer Patients | NCT05205330 | Refractory Meta... Solid Tumor Metastatic Micr... Mismatch Repair... | CR6086 AGEN2034 | 18 Years - | Rottapharm Biotech | |
| Efficacy of Cadonilimab in Non-squamous Non-small Cell Lung Cancer Patients Resistant to EGFR-TKI | NCT06277674 | Non-small Cell ... | Cadonilimab plu... | 65 Years - | Guangzhou University of Traditional Chinese Medicine | |
| Immune-Related Adverse Events and Associated Biomarkers in Patients Receiving Cancer Immunotherapy | NCT06089967 | Cancer Immune-related ... | Medical chart r... | 18 Years - | Duke University | |
| Radiotherapy Combined With ICIs as Treatment for LA-NSCLC After Failing Induction Immunochemotherapy | NCT06031597 | Non-small Cell ... | radiotherapy Platinum-Based ... Immunotherapy Immunotherapeut... | 18 Years - 75 Years | Zhejiang Cancer Hospital | |
| PD-1 Antibody and Radiotherapy for Recurrent Cervical Cancer | NCT05310305 | Immune Checkpoi... Anti-programmed... Radiotherapy Recurrent Cervi... Metastatic Cerv... Persistent Adva... Objective Remis... Progression-fre... Overall Surviva... Severe Adverse ... | Radiotherapy fo... | 18 Years - | Peking Union Medical College Hospital | |
| Immune CHeckpoint Inhibitors Monitoring of Adverse Drug ReAction | NCT03492242 | Arthritis Cancer Cardiac Disease Endocrine Syste... Autoimmune Dise... Ophthalmopathy Myositis Neuropathy | Immune checkpoi... | 18 Years - | Groupe Hospitalier Pitie-Salpetriere | |
| TACE in Combination With PD-1/PD-L1 Inhibitors and Molecular Target Therapies for Advanced HCC | NCT05332821 | Hepatocellular ... | PD-1/PD-L1 inhi... TACE | 18 Years - | Zhongda Hospital | |
| Upfront Immune Checkpoint Inhibitors With Deferred Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma | NCT06279403 | Clear-cell Meta... Immune Checkpoi... Cytoreductive N... | Toripalimab Cytoreductive N... Axitinib | 18 Years - 80 Years | RenJi Hospital | |
| Postoperative Radiotherapy Followed by Immunotherapy for Locally Advanced Esophageal Carcinoma | NCT05937438 | Esophageal Carc... | Immune Checkpoi... | 18 Years - 75 Years | Anhui Provincial Hospital | |
| Safety and Preliminary Efficacy of BNT314 With or Without an Immune Checkpoint Inhibitor in Cancer Patients With Malignant Solid Tumors | NCT06150183 | Advanced Malign... | BNT314 Pembrolizumab | 18 Years - | BioNTech SE | |
| Exploring the Efficacy, Safety and Cost-effectiveness Analysis of Cadonilimab in the Treatment of Cervical Cancer | NCT06140589 | Cervical Cancer | Cadonilimab | 18 Years - 80 Years | Fujian Cancer Hospital | |
| VERIFY: Vedolizumab for the Prevention of Immune Checkpoint Inhibitor Related Diarrhea or Colitis in Patients With Cancer | NCT06337695 | Cancer Cancer Metastat... | Vedolizumab Placebo | 18 Years - | University of Calgary | |
| Treatment Efficacy of Corticosteroids and Mycophenolate Mofetil in Patients With Immune Related Hepatitis | NCT04810156 | Hepatitis, Drug... | Mycophenolate M... Solu-Medrol Ursodeoxycholic... Prednisone tabl... | 18 Years - | Herlev Hospital | |
| Postoperative Radiotherapy Followed by Immunotherapy for Locally Advanced Esophageal Carcinoma | NCT05937438 | Esophageal Carc... | Immune Checkpoi... | 18 Years - 75 Years | Anhui Provincial Hospital | |
| VERIFY: Vedolizumab for the Prevention of Immune Checkpoint Inhibitor Related Diarrhea or Colitis in Patients With Cancer | NCT06337695 | Cancer Cancer Metastat... | Vedolizumab Placebo | 18 Years - | University of Calgary | |
| A Perspective, Self-control Study on the Progression of Carotid Plaques in Anti-PD-1 mAb Treated Tumor Patients by Artery Ultrasound Follow-up | NCT05123287 | Plaque, Atheros... Immune Checkpoi... Programmed Cell... Carotid Artery ... Intimal Medial ... | PD-1 immune che... | 18 Years - 90 Years | Second Affiliated Hospital, School of Medicine, Zhejiang University | |
| TACE in Combination With PD-1/PD-L1 Inhibitors and Molecular Target Therapies for Intermediate HCC | NCT05332496 | Hepatocellular ... | PD-1/PD-L1 inhi... TACE | 18 Years - | Zhongda Hospital | |
| CICLOPS Immune Checkpoint Inhibitors Neurotoxicity: Long-term Outcomes, Predictors, and Survival. | NCT05942872 | Paraneoplastic ... | This is a non-i... | 18 Years - | Hospices Civils de Lyon | |
| Neoadjuvant Tislelizumab With Chemotherapy for the Treatment of MSS Colon Cancer | NCT06124378 | Colonic Neoplas... Neoadjuvant The... Immune Checkpoi... | Tislelizumab Oxaliplatin Capecitabine Colectomy | 18 Years - 75 Years | First Affiliated Hospital of Guangxi Medical University | |
| Exploring the Efficacy, Safety and Cost-effectiveness Analysis of Cadonilimab in the Treatment of Cervical Cancer | NCT06140589 | Cervical Cancer | Cadonilimab | 18 Years - 80 Years | Fujian Cancer Hospital | |
| Fertility and Pregnancy After Avelumab Treatment | NCT06242522 | Gestational Tro... Immune Checkpoi... | Telephone inter... | 18 Years - | Hospices Civils de Lyon | |
| Safety and Modulation of Adaptive Immunity by Iscador® Qu Viscum Album Extract in Patients With Advanced, Recurrent or Metastatic Cancers Treated With Immune Checkpoint Inhibitors | NCT06408688 | Advanced Solid ... | Immune checkpoi... Immune Checkpoi... | 18 Years - | University Hospital, Basel, Switzerland | |
| A Study of Concomitant Camrelizumab With Chemoradiation for Locally Advanced Head and Neck Cancer | NCT04405154 | Head and Neck N... | Camrelizumab Cisplatin IMRT or VMAT | 18 Years - 75 Years | West China Hospital | |
| Study of Chemoradiotherapy With Envafolimab For The Treatment of Locally Advanced Cervical Cancer | NCT05799469 | Locally Advance... | Envafolimab Cisplatin External Beam R... Brachytherapy (... | 18 Years - 75 Years | Chongqing University Cancer Hospital | |
| irAE Prediction of Anti-PD-1/L1 in Lung Cancer | NCT05288569 | Immune Checkpoi... Lung Cancer | 18 Years - 80 Years | Peking Union Medical College Hospital | ||
| Oncolytic Virus (OVV-01) Injection in the Treatment of Patients With Advanced Solid Tumors | NCT04787003 | Neoplasms | oncolytic virus... | 18 Years - 70 Years | North China Petroleum Bureau General Hospital | |
| A Study of Camrelizumab Combined Apatinib in Hepatocellular Carcinoma Previously Treated With Immune Checkpoint Inhibitors (ICIs). | NCT04826406 | Hepatocellular ... Immune Checkpoi... | Camrelizumab co... | 18 Years - | Hunan Cancer Hospital | |
| CICLOPS Immune Checkpoint Inhibitors Neurotoxicity: Long-term Outcomes, Predictors, and Survival. | NCT05942872 | Paraneoplastic ... | This is a non-i... | 18 Years - | Hospices Civils de Lyon | |
| Study on the Treatment of Advanced Malignant Solid Tumor With Revottack and PD-1 Inhibitor | NCT05644509 | Advanced Solid ... | Oncolytic Virus... | 18 Years - | The Affiliated Hospital of Xuzhou Medical University | |
| Clinical Study on the Prevention of Driver Gene Negative II-IIIa Lung Cancer Recurrence and Metastasis by Staged Chinese Herbal Medicine Combined With Chemotherapy and Immune Checkpoint Inhibitors | NCT05834413 | Lung Cancer | chemotherapy pl... chemotherapy pl... | 18 Years - 74 Years | Shanghai University of Traditional Chinese Medicine | |
| Ph2 Study NKT2152 With Palbociclib & Sasanlimab in Subjects With Advanced Clear Cell Renal Cell Carcinoma (ccRcc) | NCT05935748 | ccRCC Clear Cell Rena... Kidney Cancer Kidney Neoplasm... Renal Cancer Renal Neoplasms Recurrent Renal... Metastatic Rena... Refractory Rena... Advanced Renal ... Carcinoma Neoplasms Carcinoma, Rena... Neoplasms, Glan... Neoplasm by His... Adenocarcinoma Urologic Neopla... Urogenital Neop... Neoplasms by Si... Kidney Diseases Urologic Diseas... | NKT2152 palbociclib sasanlimab | 18 Years - | NiKang Therapeutics, Inc. | |
| Safety and Preliminary Efficacy of BNT314 With or Without an Immune Checkpoint Inhibitor in Cancer Patients With Malignant Solid Tumors | NCT06150183 | Advanced Malign... | BNT314 Pembrolizumab | 18 Years - | BioNTech SE | |
| CICLOPS Immune Checkpoint Inhibitors Neurotoxicity: Long-term Outcomes, Predictors, and Survival. | NCT05942872 | Paraneoplastic ... | This is a non-i... | 18 Years - | Hospices Civils de Lyon | |
| The Conversion Therapy of Chemotherapy Plus Camrelizumab in Metastatic Gastric Cancer | NCT04694183 | Stomach Neoplas... | Camrelizumab S-1 Oxaliplatin Paclitaxel | 18 Years - 75 Years | The First Hospital of Jilin University | |
| Trial of PBF-509 and PDR001 in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) | NCT02403193 | Non-small Cell ... | PBF-509_80 mg PBF-509_160 mg PBF-509_320 mg PBF-509_640 mg Combo PBF-509 (... Combo PBF-509 (... Combo PBF-509 (... RP2D (PBF-509+P... Experimental: R... | 18 Years - | Palobiofarma SL | |
| Clinical Study on the Prevention of Driver Gene Negative II-IIIa Lung Cancer Recurrence and Metastasis by Staged Chinese Herbal Medicine Combined With Chemotherapy and Immune Checkpoint Inhibitors | NCT05834413 | Lung Cancer | chemotherapy pl... chemotherapy pl... | 18 Years - 74 Years | Shanghai University of Traditional Chinese Medicine | |
| A Study of Pembrolizumab With Standard Treatment in Patients With Recurrent Platinum-resistant Ovarian Cancer | NCT02608684 | Ovarian Cancer | Pembrolizumab Gemcitabine Cisplatin | 18 Years - | Cedars-Sinai Medical Center | |
| Ipilimumab With Nivolumab for Molecular-selected Patients With Castration-resistant Prostate Cancer | NCT04717154 | Prostatic Neopl... | Ipilimumab Nivolumab | 18 Years - | Radboud University Medical Center | |
| TACE in Combination With PD-1/PD-L1 Inhibitors and Molecular Target Therapies for Intermediate HCC | NCT05332496 | Hepatocellular ... | PD-1/PD-L1 inhi... TACE | 18 Years - | Zhongda Hospital | |
| Tislelizumab and Radiotherapy for Recurrent Cervical Cancer | NCT05310383 | Recurrent Cervi... Metastatic Cerv... Persistent Cerv... Radiotherapy Immunotherapy Anti-programmed... Immune Checkpoi... Tislelizumab Objective Respo... Survival Outcom... | Tislelizumab pl... | 18 Years - | Peking Union Medical College Hospital | |
| Autoantibodies in Treatment With Immune Checkpoint Inhibitors (AUTENTIC) | NCT03868046 | Cancer Metastatic Canc... Solid Organ Can... | Treatment with ... Blood tests. | 16 Years - 99 Years | Hospital Universitario Araba | |
| Observational Basket Trial to Collect Tissue to Train and Validate a Live Tumor Diagnostic Platform | NCT05520099 | Colorectal Canc... Head and Neck S... Non Small Cell ... Cutaneous Melan... Endometrial Can... Urothelial Carc... Clear Cell Rena... | Core Needle or ... | 18 Years - | Elephas | |
| Oncolytic Virus (OVV-01) Injection in the Treatment of Patients With Advanced Solid Tumors | NCT04787003 | Neoplasms | oncolytic virus... | 18 Years - 70 Years | North China Petroleum Bureau General Hospital | |
| The Conversion Therapy of Chemotherapy Plus Camrelizumab in Metastatic Gastric Cancer | NCT04694183 | Stomach Neoplas... | Camrelizumab S-1 Oxaliplatin Paclitaxel | 18 Years - 75 Years | The First Hospital of Jilin University | |
| SBRT for Oligoprogressive NSCLC After First Line Treatment With Immune Checkpoint Inhibitors | NCT05387044 | NSCLC Stage IV | SBRT | 18 Years - | Zhejiang Cancer Hospital | |
| Phase II Trial of Consolidative Thoracic Radiotherapy for ES-SCLC After Standard Care of Chemo-immunotherapy | NCT05552846 | Small-cell Lung... | thoracic radiot... | 18 Years - 80 Years | Ruijin Hospital | |
| PD-1 Antibody Versus Best Supportive Care After Chemoradiation in Locoregionally Advanced Nasopharyngeal Carcinoma | NCT03427827 | Nasopharyngeal ... | Camrelizumab | 18 Years - 65 Years | Sun Yat-sen University | |
| Biomarkers of Immune-Related Toxicity | NCT03409016 | Cancer Metastatic Canc... | Blood Testing | 18 Years - 100 Years | University of Colorado, Denver | |
| A Study of Oncolytic Virus Injection (RT-01) in Combination With PD-1 Inhibitor in Patients With Advanced Solid Tumors | NCT05228119 | Advanced Solid ... | Oncolytic Virus... | 18 Years - | The Affiliated Hospital of Xuzhou Medical University | |
| Cadonilimab in the Treatment of Recurrent/Metastatic Nasopharyngeal Carcinoma | NCT05898256 | Nasopharyngeal ... Immune Checkpoi... | Cadonilimab Gemcitabine Cisplatin | 18 Years - 65 Years | Guangxi Medical University | |
| Upfront Immune Checkpoint Inhibitors With Deferred Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma | NCT06279403 | Clear-cell Meta... Immune Checkpoi... Cytoreductive N... | Toripalimab Cytoreductive N... Axitinib | 18 Years - 80 Years | RenJi Hospital | |
| The Efficacy of Chemotherapy Combined With Immunocheckpoint Inhibitors in Advanced Biliary Malignancies | NCT05487443 | Gemcitabine Biliary Tract C... Immune Checkpoi... | Gemcitabine-bas... | 18 Years - 80 Years | First People's Hospital of Hangzhou | |
| Immune-Related Adverse Events and Associated Biomarkers in Patients Receiving Cancer Immunotherapy | NCT06089967 | Cancer Immune-related ... | Medical chart r... | 18 Years - | Duke University | |
| Exploratory Study on the Therapeutic Effect Prediction Model of Advanced BTC Immunotherapy | NCT06074029 | Biliary Tract C... Immune Checkpoi... Predictive Canc... | Immune Checkpoi... | 18 Years - 80 Years | Peking Union Medical College Hospital |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
